Developer docs
API playgroundTry for free, no card

Search company profiles

Artis BioSolutions

Full company profile

uuid000bmch

Namestring
Artis BioSolutions
Legal namestring
Artis BioSolutions
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Artis BioSolutions is a privately held contract development and manufacturing organization (CDMO) focused on advancing genetic medicines and biologics from early development through commercial readiness. The company serves advanced therapy medicinal product (ATMP) developers—specifically those working in cell and gene therapy, mRNA therapeutics, peptide therapies, and oligonucleotide therapies—through an integrated platform spanning nucleic acid manufacturing, lipid nanoparticle (LNP) formulation, peptide manufacturing, and analytical development services. Artis positions itself as a "growth equity accelerator" rather than a pure transactional CDMO, offering capital support, technical expertise, and a partner network to small and mid-size founder-led companies in North America and Europe.

The company's technical foundation combines organic build-out with targeted acquisitions. In April 2025, Artis emerged from stealth and acquired Landmark Bio, a cell and gene therapy CDMO with GMP manufacturing operations in Watertown, Massachusetts. In January 2026, it acquired Syngoi Technologies—a Spanish biotechnology company founded in 2021 in the Basque Country—from Buenavista Equity Partners and Columbus Venture Partners, gaining a proprietary enzymatic synthetic DNA platform and GMP-ready facilities in Bilbao. These assets are being integrated into a transatlantic manufacturing footprint of seven clinical-to-commercial GMP facilities representing over $250M of deployed capital, anchored by a new synthetic DNA manufacturing hub in Boston launched in March 2026. Leadership comprises founder-CEO Brian Neel (25 years in life sciences/diagnostics), founder-CSO Mike Houston, Ph.D. (oligonucleotide, LNP, and analytical development expertise), CSIO Dr. Kate Broderick, Ph.D. (appointed February 2026 from Maravai LifeSciences and Inovio Pharmaceuticals), CBO Peter Stolba, and SVP of People Leeza Frantz.

Artis generates revenue through professional-services contract manufacturing and development engagements with ATMP sponsors, priced via bespoke quotes rather than public rate cards, and engaged through direct enterprise sales. Its GTM targets founder-led small-to-mid-size therapy developers and corporate partners seeking to scale or commercialize novel products. The company's stated competitive advantages are capital intensity (the seven-facility footprint), proprietary enzymatic DNA synthesis technology from Syngoi, deep talent across multiple modalities (50+ APIs/CRMs developed by leadership), and a dual-region U.S./Europe manufacturing strategy that reduces supply-chain risk for clients.

Short descriptiontext

Artis BioSolutions is a private CDMO providing GMP manufacturing and development services for advanced therapy developers across cell & gene, mRNA, peptide, and oligonucleotide modalities, operating seven facilities in the U.S. and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract development manufacturing, advanced therapy manufacturing, cell and gene therapy CDMO, nucleic acid manufacturing services, lipid nanoparticle formulation
Industry4 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Development and Manufacturing (CDMO) for Advanced Therapies
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services (CDMO)
TypeProfessional Services
Description

Artis BioSolutions generates revenue through contract development and manufacturing services for advanced therapy developers. The company provides GMP manufacturing capabilities across multiple therapeutic modalities including cell & gene therapy, mRNA, peptides, and oligonucleotide therapies, supporting clients from Phase 1 through commercial production.

artisbiosolutions.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Artis BioSolutions is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing services for advanced therapy medicinal products (ATMPs) including nucleic acids (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticles (LNPs), peptides, enzymes, and reagents. The company supports drug development from Phase 1 trials through commercial readiness across cell & gene, mRNA, peptide, and oligonucleotide therapy modalities. Services are delivered through seven clinical-to-commercial GMP facilities in the U.S. and Europe via its Landmark Bio (Watertown, MA) and Syngoi Technologies (Bilbao, Spain) entities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduced lead times, logistics costs, and geopolitical/operational risks through dual-region sourcing
Product overview1 text field

Artis BioSolutions is an advanced-therapies development and manufacturing company offering a comprehensive platform for genetic medicines and biologics. The portfolio includes nucleic acid manufacturing services (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticle (LNP) formulation services, peptide manufacturing, and analytical development services. The company operates through two key acquired entities: Landmark Bio (GMP manufacturing facilities in Watertown, MA) and Syngoi Technologies (enzymatic synthetic DNA platform with GMP-ready facilities in Bilbao, Spain). Services support drug development from Phase 1 trials through commercial readiness across diverse modalities including cell & gene therapy, mRNA, peptides, and oligonucleotides. The company has deployed over $250M of capital across seven state-of-the-art clinical to commercial GMP facilities.

Product and service1 record
1Nucleic Acid Manufacturing Services
CategoryCore CDMO Service
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Artis BioSolutions acquired Landmark Bio, a cell and gene therapy manufacturer, as part of its emergence from stealth. Landmark Bio operates as a wholly-owned entity of Artis BioSolutions, expanding the company's manufacturing and commercialization capabilities for advanced therapies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Artis BioSolutions acquired Syngoi Technologies, a Spanish biotechnology company pioneering enzymatic approaches for synthetic DNA manufacturing. Syngoi operates GMP-ready facilities in Bilbao, Spain. The acquisition expands Artis' synthetic DNA capabilities and is part of a dual-sourcing strategy across U.S. and Europe.

3Advanced Therapy Medicinal Product Developers
Strategic tierCoreTypeOthers
Description

Artis BioSolutions partners with and provides services to advanced therapy developers. The company is actively seeking partners with innovative platforms or capabilities that will catalyze success for ATMP developers, with a focus on founder-led companies in North America or Europe.

artisbiosolutions.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Technology-enabled CDMO focused on advanced therapy manufacturing, including cell, gene and nucleic acid modalities—an emerging challenger with comparable modality breadth and a similar growth-equity profile.

TypeDirect peer
Description

CDMO division of GenScript offering plasmid DNA, viral vector, mRNA and cell therapy manufacturing—directly comparable to Artis' nucleic acid and cell therapy capabilities.

TypeDirect peer
Description

Leading plasmid DNA, mRNA and protein CDMO serving gene and cell therapy developers—directly comparable to Artis' synthetic DNA and nucleic acid manufacturing offering.

TypeDirect peer
Description

Global CDMO with one of the largest cell, gene and mRNA therapy manufacturing footprints, including mammalian biologics and LNP formulation—Artis' most direct full-service competitor across nucleic acids and advanced therapies.

TypeDirect peer
Description

Large diversified CDMO with deep cell and gene therapy capabilities, including viral vector and nucleic acid manufacturing—directly comparable to Artis in advanced therapy modalities.

TypeDirect peer
Description

Specialized nucleic acid CDMO (mRNA, oligonucleotides, plasmid DNA) with GMP-grade synthetic capabilities—Artis' closest direct competitor in the nucleic acid manufacturing niche.

TypeDirect peer
Description

Cell and gene therapy CDMO offering viral vector and nucleic acid manufacturing for global ATMP developers—historically the largest competitor to emerging CDMOs, though currently facing US geopolitical headwinds.

TypeDirect peer
Description

Global CDMO offering mammalian biologics and cell/gene therapy manufacturing, including recently expanded viral vector and nucleic acid capacity—a comparable mid-to-large advanced therapy CDMO.

TypeBroad incumbent
Description

Established CDMO with a dedicated cell and gene therapy manufacturing business and integrated discovery-to-development services, overlapping Artis' modalities and end customers.

TypeBroad incumbent
Description

Large-scale biologics CDMO with growing cell and gene therapy services, providing a broad manufacturing platform that overlaps with Artis' clinical-to-commercial offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Artis BioSolutions

Contract Development and Manufacturing (CDMO) for Advanced Therapiesartisbiosolutions.com

Artis BioSolutions is a private CDMO providing GMP manufacturing and development services for advanced therapy developers across cell & gene, mRNA, peptide, and oligonucleotide modalities, operating seven facilities in the U.S. and Europe.

What Artis BioSolutions does

Artis BioSolutions is a privately held contract development and manufacturing organization (CDMO) focused on advancing genetic medicines and biologics from early development through commercial readiness. The company serves advanced therapy medicinal product (ATMP) developers—specifically those working in cell and gene therapy, mRNA therapeutics, peptide therapies, and oligonucleotide therapies—through an integrated platform spanning nucleic acid manufacturing, lipid nanoparticle (LNP) formulation, peptide manufacturing, and analytical development services. Artis positions itself as a "growth equity accelerator" rather than a pure transactional CDMO, offering capital support, technical expertise, and a partner network to small and mid-size founder-led companies in North America and Europe.

The company's technical foundation combines organic build-out with targeted acquisitions. In April 2025, Artis emerged from stealth and acquired Landmark Bio, a cell and gene therapy CDMO with GMP manufacturing operations in Watertown, Massachusetts. In January 2026, it acquired Syngoi Technologies—a Spanish biotechnology company founded in 2021 in the Basque Country—from Buenavista Equity Partners and Columbus Venture Partners, gaining a proprietary enzymatic synthetic DNA platform and GMP-ready facilities in Bilbao. These assets are being integrated into a transatlantic manufacturing footprint of seven clinical-to-commercial GMP facilities representing over $250M of deployed capital, anchored by a new synthetic DNA manufacturing hub in Boston launched in March 2026. Leadership comprises founder-CEO Brian Neel (25 years in life sciences/diagnostics), founder-CSO Mike Houston, Ph.D. (oligonucleotide, LNP, and analytical development expertise), CSIO Dr. Kate Broderick, Ph.D. (appointed February 2026 from Maravai LifeSciences and Inovio Pharmaceuticals), CBO Peter Stolba, and SVP of People Leeza Frantz.

Artis generates revenue through professional-services contract manufacturing and development engagements with ATMP sponsors, priced via bespoke quotes rather than public rate cards, and engaged through direct enterprise sales. Its GTM targets founder-led small-to-mid-size therapy developers and corporate partners seeking to scale or commercialize novel products. The company's stated competitive advantages are capital intensity (the seven-facility footprint), proprietary enzymatic DNA synthesis technology from Syngoi, deep talent across multiple modalities (50+ APIs/CRMs developed by leadership), and a dual-region U.S./Europe manufacturing strategy that reduces supply-chain risk for clients.

Artis BioSolutions firmographics

Firmographics
Name
Artis BioSolutions
Legal name
Artis BioSolutions
Website
https://artisbiosolutions.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
101–250 employees
Short description
Artis BioSolutions is a private CDMO providing GMP manufacturing and development services for advanced therapy developers across cell & gene, mRNA, peptide, and oligonucleotide modalities, operating seven facilities in the U.S. and Europe.
Ownership category
akta.pro rank

Artis BioSolutions industry classification

Industry
Product category
Contract Development and Manufacturing (CDMO) for Advanced Therapies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract development manufacturing
  • Advanced therapy manufacturing
  • Cell and gene therapy CDMO
  • Nucleic acid manufacturing services
  • Lipid nanoparticle formulation

Where Artis BioSolutions is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Artis BioSolutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

  1. Contract Manufacturing Services (CDMO): Artis BioSolutions generates revenue through contract development and manufacturing services for advanced therapy developers. The company provides GMP manufacturing capabilities across multiple therapeutic modalities including cell & gene therapy, mRNA, peptides, and oligonucleotide therapies, supporting clients from Phase 1 through commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Artis BioSolutions product offering

Product offering

Core offering

Artis BioSolutions is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing services for advanced therapy medicinal products (ATMPs) including nucleic acids (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticles (LNPs), peptides, enzymes, and reagents. The company supports drug development from Phase 1 trials through commercial readiness across cell & gene, mRNA, peptide, and oligonucleotide therapy modalities. Services are delivered through seven clinical-to-commercial GMP facilities in the U.S. and Europe via its Landmark Bio (Watertown, MA) and Syngoi Technologies (Bilbao, Spain) entities.

Product overview

Artis BioSolutions is an advanced-therapies development and manufacturing company offering a comprehensive platform for genetic medicines and biologics. The portfolio includes nucleic acid manufacturing services (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticle (LNP) formulation services, peptide manufacturing, and analytical development services. The company operates through two key acquired entities: Landmark Bio (GMP manufacturing facilities in Watertown, MA) and Syngoi Technologies (enzymatic synthetic DNA platform with GMP-ready facilities in Bilbao, Spain). Services support drug development from Phase 1 trials through commercial readiness across diverse modalities including cell & gene therapy, mRNA, peptides, and oligonucleotides. The company has deployed over $250M of capital across seven state-of-the-art clinical to commercial GMP facilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nucleic Acid Manufacturing Services

Quantifiable outcome

  • Reduced lead times, logistics costs, and geopolitical/operational risks through dual-region sourcing

Companies that use Artis BioSolutions

Customer profile

Segments1 record

Ideal customer profiles1 record

Artis BioSolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Artis BioSolutions partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Landmark BiocoreStrategic or Co-development Partner · 1 April 2025Artis BioSolutions acquired Landmark Bio, a cell and gene therapy manufacturer, as part of its emergence from stealth. Landmark Bio operates as a wholly-owned entity of Artis BioSolutions, expanding the company's manufacturing and commercialization capabilities for advanced therapies.
  • Syngoi TechnologiescoreStrategic or Co-development PartnerArtis BioSolutions acquired Syngoi Technologies, a Spanish biotechnology company pioneering enzymatic approaches for synthetic DNA manufacturing. Syngoi operates GMP-ready facilities in Bilbao, Spain. The acquisition expands Artis' synthetic DNA capabilities and is part of a dual-sourcing strategy across U.S. and Europe.
  • Advanced Therapy Medicinal Product DeveloperscoreOthersArtis BioSolutions partners with and provides services to advanced therapy developers. The company is actively seeking partners with innovative platforms or capabilities that will catalyze success for ATMP developers, with a focus on founder-led companies in North America or Europe.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Artis BioSolutions competitors and assessment

Company assessment

Emerging players

  • Resilience: Technology-enabled CDMO focused on advanced therapy manufacturing, including cell, gene and nucleic acid modalities—an emerging challenger with comparable modality breadth and a similar growth-equity profile.

Direct peers

  • GenScript ProBio: CDMO division of GenScript offering plasmid DNA, viral vector, mRNA and cell therapy manufacturing—directly comparable to Artis' nucleic acid and cell therapy capabilities.
  • Aldevron (Danaher): Leading plasmid DNA, mRNA and protein CDMO serving gene and cell therapy developers—directly comparable to Artis' synthetic DNA and nucleic acid manufacturing offering.
  • Lonza: Global CDMO with one of the largest cell, gene and mRNA therapy manufacturing footprints, including mammalian biologics and LNP formulation—Artis' most direct full-service competitor across nucleic acids and advanced therapies.
  • Catalent (Novo Holdings): Large diversified CDMO with deep cell and gene therapy capabilities, including viral vector and nucleic acid manufacturing—directly comparable to Artis in advanced therapy modalities.
  • TriLink BioTechnologies (Maravai LifeSciences): Specialized nucleic acid CDMO (mRNA, oligonucleotides, plasmid DNA) with GMP-grade synthetic capabilities—Artis' closest direct competitor in the nucleic acid manufacturing niche.
  • WuXi Advanced Therapies (WuXi AppTec): Cell and gene therapy CDMO offering viral vector and nucleic acid manufacturing for global ATMP developers—historically the largest competitor to emerging CDMOs, though currently facing US geopolitical headwinds.
  • AGC Biologics: Global CDMO offering mammalian biologics and cell/gene therapy manufacturing, including recently expanded viral vector and nucleic acid capacity—a comparable mid-to-large advanced therapy CDMO.

Broad incumbents

  • Charles River Laboratories: Established CDMO with a dedicated cell and gene therapy manufacturing business and integrated discovery-to-development services, overlapping Artis' modalities and end customers.
  • Samsung Biologics: Large-scale biologics CDMO with growing cell and gene therapy services, providing a broad manufacturing platform that overlaps with Artis' clinical-to-commercial offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Artis BioSolutions social profiles

Digital presence

Artis BioSolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Artis BioSolutions leadership team

Management profile

Number of profiles

Profiles5 records

Artis BioSolutions subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Artis BioSolutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Artis BioSolutions M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artis BioSolutions

What does Artis BioSolutions do?

Artis BioSolutions is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing services for advanced therapy medicinal products (ATMPs) including nucleic acids (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticles (LNPs), peptides, enzymes, and reagents. The company supports drug development from Phase 1 trials through commercial readiness across cell & gene, mRNA, peptide, and oligonucleotide therapy modalities. Services are delivered through seven clinical-to-commercial GMP facilities in the U.S. and Europe via its Landmark Bio (Watertown, MA) and Syngoi Technologies (Bilbao, Spain) entities.

Is Artis BioSolutions a public or private company?

Artis BioSolutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Artis BioSolutions founded?

Artis BioSolutions was founded in 2025. It employs 101 to 250 people.

Where is Artis BioSolutions based?

Artis BioSolutions is headquartered in Carlsbad, United States, in the North America region.

How does Artis BioSolutions make money?

One revenue line is on record: contract Manufacturing Services (CDMO).

Who are Artis BioSolutions's main competitors?

Resilience is listed as an emerging player. Direct peers are GenScript ProBio, Aldevron (Danaher), Lonza, Catalent (Novo Holdings), TriLink BioTechnologies (Maravai LifeSciences), WuXi Advanced Therapies (WuXi AppTec) and AGC Biologics. Broad incumbents are Charles River Laboratories and Samsung Biologics.

Does Artis BioSolutions have an API?

No public API is recorded for Artis BioSolutions.

What industry is Artis BioSolutions in?

Artis BioSolutions's product category is Contract Development and Manufacturing (CDMO) for Advanced Therapies. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Genengnews10 CDMO Up & Comers 2026Ten CDMOs are listed as up-and-comers for 2026, including Artis BioSolutions, AsymBio, and Bora Group, with actions such as acquisitions, contracts, and facility openings. Bora Group completed a $127.5 million acquisition of MacroGenics and signed a $250 million GSK contract, while Resilience expanded its Eli Lilly partnership with a $750 million expansion.FiercePharmaArtis BioSolutions expands synthetic DNA, mRNA production with Spanish facilityArtis BioSolutions, a San Diego-based CDMO, opened a new manufacturing center in Bilbao, Spain, expanding its Genetic Medicines Center of Excellence for synthetic DNA, mRNA, lipid nanoparticle formulation and GMP production. Financial details were not disclosed. Artis launched as a CDMO in April 2025 after acquiring Landmark Bio for an undisclosed price, including a 44,000-square-foot Watertown, Massachusetts site.FinancialContent Business PageArtis BioSolutions Launches mRNA and Lipid Nanoparticle Manufacturing Capabilities at New “Genetic Medicines Center of Excellence” in Bilbao, SpainArtis BioSolutions announced the launch of its Genetic Medicines Center of Excellence in Bilbao, Spain, offering synthetic DNA, mRNA drug substance, lipid nanoparticle formulation and GMP drug product manufacturing. CEO Brian Neel called it a defining milestone, citing reduced technology transfer burdens and faster program advancement. The facility complements Artis' Boston site in Watertown, Massachusetts.BioSpaceArtis BioSolutions Launches mRNA and Lipid Nanoparticle Manufacturing Capabilities at New “Genetic Medicines Center of Excellence” in Bilbao, SpainArtis BioSolutions launched its Genetic Medicines Center of Excellence in Bilbao, Spain, integrating synthetic DNA, mRNA, lipid nanoparticle, and GMP drug product capabilities. The center aims to streamline development and manufacturing for genetic medicines, reducing technology transfer burdens and accelerating programs from early development through commercialization.FinancialContent Business PageLandmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic MedicinesArtis BioSolutions announced that Landmark Bio (Watertown, Massachusetts) and Syngoi (Bilbao, Spain) will now operate under a unified Artis BioSolutions brand, completing a transatlantic platform that connects synthetic DNA production with downstream development and GMP manufacturing for genetic medicines. The company, which secured a $18.3 million award from ARPA-H in April for the TRANSFORM EV project on scalable continuous manufacturing for extracellular vesicle therapies, is positioning itself as a single integrated alternative to fragmented supply chains in the advanced therapy industry. Artis BioSolutions is based in San Diego and operates production sites in both the United States and Spain.GenengnewsSynthetic DNA Manufacturing Hub Set Up in Boston by Artis BioSolutionsArtis BioSolutions, a San Diego-based advanced therapies company, has established new synthetic DNA manufacturing capabilities in Boston using Bilbao, Spain-based Syngoi Technologies' proprietary enzymatic platform. This expansion integrates with the company's existing GMP manufacturing facility in Watertown, MA, establishing a dual-sourcing strategy across the U.S. and Europe to reduce lead times, logistics costs, and mitigate geopolitical and operational risks associated with single-region sourcing. The company states this positions its specialized technical expertise in immediate proximity to key U.S. clients and strategic partners while enhancing service continuity for its global customer base.STATUp and down the ladder: The latest comings and goingsArtis BioSolutions announced the hiring of Kate Broderick as chief scientific innovation officer; Broderick previously served as senior vice president of R&D at Inovio Pharmaceuticals. The article functions as a routine industry personnel news column seeking reader submissions about hiring and promotion announcements. The Pharmalot newsletter feature appears to be a recurring industry tracker focused on executive movement within the pharmaceutical sector.PharmiWeb.comArtis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA StrategyArtis BioSolutions appointed Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer, effective February 9, 2026, to lead scientific strategy and innovation across the company's platform supporting next-generation genetic medicines development and manufacturing. Dr. Broderick brings over 25 years of experience in nucleic acid medicine and previously held senior roles at Maravai LifeSciences and Inovio Pharmaceuticals. The appointment is strategically tied to the pending acquisition of Syngoi Technologies, expected to close in Q1 2026, which will expand Artis's synthetic DNA capabilities.Business Wire BlogArtis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA StrategyArtis BioSolutions announced the appointment of Dr. Kate Broderick as Chief Scientific Innovation Officer, effective February 9, 2026, to lead scientific strategy across the company's platform supporting next-generation genetic medicines. The appointment is directly connected to the company's pending acquisition of Syngoi Technologies, which is expected to close in Q1 2026, subject to customary closing conditions. Dr. Broderick brings over 25 years of experience in nucleic acid medicine and previously held senior roles at Maravai LifeSciences and Inovio Pharmaceuticals.InvestorsinhealthcareSpain: Artis BioSolutions acquires CDMO Syngoi TechnologiesUS-based biotech Artis BioSolutions has acquired Spain-based CDMO Syngoi Technologies from private equity firm Buenavista Equity Partners and venture capital firm Columbus Venture Partners. Syngoi Technologies, formed in 2021, has developed a synthetic DNA platform based on enzymatic processes designed to address production bottlenecks in the gene and cell therapy industry. The acquisition will enable Syngoi to achieve industrial scale, operational robustness, and global reach as part of Artis BioSolutions' ecosystem.